Beyond Thr172 phosphorylation: subunit-selective, spatial, and post-translational AMPK signaling in diabetic cardiomyopathy
- 1Department of Cardiology, The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine
Abstract
AMP-activated protein kinase (AMPK) is widely examined in diabetic cardiomyopathy (DCM) through total protein abundance and activation-loop phosphorylation, typically reported as p -AMPK Thr172 . Yet these measurements cannot identify the active αβγ heterotrimer, cellular source, intracellular location, or regulatory modification underlying a response. This mechanistically focused narrative review integrates experimental evidence on subunit-selective, spatial, and post-translational modification (PTM)-dependent regulation of AMPK, distinguishing DCM-specific mechanisms from findings extrapolated from other models. In diabetic cardiomyocytes, α 2-associated signaling contributes to mitochondrial homeostasis and remodeling, whereas mitochondria-associated α 1 signaling in cardiac microvascular endothelium is linked to mitochondrial quality control and microvascular protection. AMPK γ 1 emerges as a regulator of inter-subunit interactions. Mechanistic studies further show that OTUD1 and VCPIP1 regulate non-degradative K63-linked ubiquitination of AMPK α 2 and γ 1, respectively, affecting interactions with upstream kinases without substantial loss of subunit abundance. Regulatory phosphorylation and the O-GlcNAc network provide additional layers of control, although direct endogenous O-GlcNAc modification of AMPK in diabetic myocardium remains unverified. These mechanisms may shape substrate metabolism, organelle quality control, redox injury, fibrosis, and microvascular dysfunction, but increased bulk AMPK phosphorylation does not necessarily establish restored metabolic flexibility or uniformly beneficial signaling. Direct evidence for native cardiac heterotrimers, compartment-specific AMPK activity, and disease-associated modified proteoforms remains limited in human diabetic myocardium. Consequently, subunit-, PTM-, and compartment-directed interventions remain experimental therapeutic hypotheses. Defining which molecular AMPK state drives a given cardiac phenotype is a prerequisite for testing whether selective intervention improves human diabetic myocardial disease.
Related
- Exercise-Based Management of Diabetic Cardiomyopathy: Preclinical Mechanisms, Clinical Evidence, and Translational Strategies.
- Endothelin signaling in diabetic kidney disease: therapeutic targeting and translational advances
- Exercise-Mediated Regulation of Ferroptosis in Diabetic Cardiomyopathy: Mechanisms and Therapeutic Perspectives
- Targeting STAT3 to Modulate the Effectiveness of Cardioprotective Conditioning Strategies Against Myocardial Ischemia-Reperfusion Injury in Subjects With Diabetic Cardiomyopathy.
- SFPQ/S100A8 complex induces filaggrin deficiency via selective autophagy and JNK phosphorylation in atopic dermatitis.
BibTeX
@article{xia2026beyond,
title = {{Beyond Thr172 phosphorylation: subunit-selective, spatial, and post-translational AMPK signaling in diabetic cardiomyopathy}},
author = {Yebin Xia and Yuting Lin and Jinjian Guo},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
month = nov,
doi = {10.3389/fcvm.2026.1962196},
url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.1962196/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Beyond Thr172 phosphorylation: subunit-selective, spatial, and post-translational AMPK signaling in diabetic cardiomyopathy
AU - Yebin Xia
AU - Yuting Lin
AU - Jinjian Guo
PY - 2026
DA - 2026/11/05
JO - Frontiers in Cardiovascular Medicine
DO - 10.3389/fcvm.2026.1962196
UR - https://www.frontiersin.org/articles/10.3389/fcvm.2026.1962196/full
AB - AMP-activated protein kinase (AMPK) is widely examined in diabetic cardiomyopathy (DCM) through total protein abundance and activation-loop phosphorylation, typically reported as p -AMPK Thr172 . Yet these measurements cannot identify the active αβγ heterotrimer, cellular source, intracellular location, or regulatory modification underlying a response. This mechanistically focused narrative review integrates experimental evidence on subunit-selective, spatial, and post-translational modification (PTM)-dependent regulation of AMPK, distinguishing DCM-specific mechanisms from findings extrapolated from other models. In diabetic cardiomyocytes, α 2-associated signaling contributes to mitochondrial homeostasis and remodeling, whereas mitochondria-associated α 1 signaling in cardiac microvascular endothelium is linked to mitochondrial quality control and microvascular protection. AMPK γ 1 emerges as a regulator of inter-subunit interactions. Mechanistic studies further show that OTUD1 and VCPIP1 regulate non-degradative K63-linked ubiquitination of AMPK α 2 and γ 1, respectively, affecting interactions with upstream kinases without substantial loss of subunit abundance. Regulatory phosphorylation and the O-GlcNAc network provide additional layers of control, although direct endogenous O-GlcNAc modification of AMPK in diabetic myocardium remains unverified. These mechanisms may shape substrate metabolism, organelle quality control, redox injury, fibrosis, and microvascular dysfunction, but increased bulk AMPK phosphorylation does not necessarily establish restored metabolic flexibility or uniformly beneficial signaling. Direct evidence for native cardiac heterotrimers, compartment-specific AMPK activity, and disease-associated modified proteoforms remains limited in human diabetic myocardium. Consequently, subunit-, PTM-, and compartment-directed interventions remain experimental therapeutic hypotheses. Defining which molecular AMPK state drives a given cardiac phenotype is a prerequisite for testing whether selective intervention improves human diabetic myocardial disease.
SN - 2297-055X
ER -